Good afternoon and welcome to Arcadia Biosciences Fourth Quarter and Year-End 2016 Earnings Conference Call. Today's presenters will be Raj Ketkar, President and CEO; and Matt Plavan, CFO. This call is being webcast and you can refer to the Company's press release and slides at arcadiabio.com. Before we start, if you refer to Slide 2, we would like to remind you that Arcadia Biosciences will be making forward-looking statements on this call based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the Company's actual performance and results may differ materially from those described or implied today. You can review the Company's Safe Harbor language in their most recently filed 10-K and again on Slide 2 of this presentation. With that, I'll turn the call over to Raj Ketkar, President and CEO.

Thank you, Charlotte. And thanks to everyone who is joining us on the call today. I'd like to begin with an update on the business and Matt Plavan, our CFO will review the financial results of the fourth quarter and full-year 2016. At the end of the call we will, as always, take your questions. As many of you might have observed over the year, 2016 was the year of transition for Arcadia. There were management changes early in the year followed by a new CEO and CFO who started in the second and third quarter of the year. The team at Arcadia is now focused on commercialization of our product. In the third quarter we initiated a strategic review of Arcadia business to identify opportunities in light of the changes occurring in the Ag industry and reported our early findings in our last earnings call. In the fourth quarter we completed the strategic review and began to take actions to reposition the company for the future. A key outcome of the review was that Arcadia needed to evolve from a R&D focused company to a company focused on development and commercialization of near-term products. As we reported in the last quarter, regulatory processes in some countries have delayed the launch time lines for many of our high value blockbuster trades. Therefore, in the short term it becomes increasingly important for us to better manage our cash resources. We decided to focus on projects that have a higher probability of success and or a shorter time to market, such as our non-transgenic killing based product and wheat, and transgenic products in corn and soybean for north and South America, where the regulatory systems are more predictable. We also reduced the size of our organization and consolidated our facilities to reduce…

Thank you, Raj and good afternoon everyone. As Raj just explained, in this past year we've evolved our organization and our near term growth strategy to adapt to the ships in our industry and better position the company to grow in spite of the unpredictability of regulatory approval timelines. However, these industry shifts certainly affected our ability to grow the company in 2016 most notably with regard to our license, milestone and contract research revenues. As you can see in the revenue comparison chart in Slide 8, our revenues and 2016 were down meaningfully from 2015 in total by $2.2 million or 41%. Delays in granting field trial permits and other inaction by regulatory authorities delayed our expected revenue growth in three primary areas. First, our partners were unable to conduct their field trial milestones which meant we did not receive the associated milestone payments, thereby resulting in less than expected license revenues for the year. Second, these regulatory delays also shifted the projected launch dates for certain traits further into the future on average about three years which reduced the amount of license revenue recognized from upfront fees during the year while increasing the number of years over which the total revenue amounts are to be recognized. The net effect of this change in estimate is that we booked a $900,000 reversal of license revenues during the fourth quarter resulting in negative revenue at $365,000 for the quarter and only $144,000 for the entire year. Had we not had this change an estimate our license revenues would have been consistent with the prior number of $1.2 million. The third area impacting our revenues in 2016 is with our contract services revenues. Certain of our partners, differed their plans to outsource GM trait development projects to Arcadia until they have…

Thanks, Matt. Before we get to your question let me just say that I'm really pleased with the progress that Arcadia's made since I joined about nine months ago. In the last quarter, the team at Arcadia has made some bold changes reposition the company for success in the future. We are confident that these changes will result in greater and positive returns to our investors. I believe we have an exciting future and we are committed to make Arcadia successful. I look forward to reporting on our progress in 2017. And with that I'd like to turn the call over to your question now.

[Operator Instructions] Our first question comes from the line of Tyler Etten from Piper Jaffray. Your line is now open.

Hi, good afternoon thanks for taking my question. First, can you talk about maybe where nutrition have been to 20q7 and 2018 with rolling out toward some more new products, just how you see that business involving over the next one to two years.

Yes, I think the main growth that we'll see in 2017 is on GLA like we had -- like I mentioned you know we have gotten the grass notifications from FDA that allows us to go into some newer markets in nutritional beverage and medical foods, and then we've got indication from FDA, they're processing our submission of application for approval for pet foods, so we are hoping that once we get that that would also improve and increase our market size for GLA and improve -- get some revenue growth in GLA that way. The next product would be I believe Resistant Starch wheat, we're getting closer, it's kind of hard to say exactly when we would launch but it would be -- it will largely depend on our partners also that we're working with the processors and food companies that are putting the Resistant Starch wheat put into their formulation for example and bread and pasta and other products, they're doing consumer testing and so once that is done, we will see that product start to commercialize, so we don't have a specific date on the launch for that yet.

Got it. Just clarify on the pet foot process, where that process are you are you with the approvals and what steps need to be taken after the current approval is passed?

Once we get the approval we would obviously be notifying our prospective customers in the pet food business and they would be able to then potentially start ordering right away or very soon and then they're putting it into formulations and starting to sell that product, there's no other work that needed in terms of development activity beyond what's already been done.

Got it, alright. And then do you have any kind of rough idea of what you would be looking out for a cash burn in 2017. Just any sort of -- I know you spend directionally down but any sort of ratings would be helpful.

At this point Tyler, I think the guidance that it is going to be down about as much as we're comfortable with. And to the extent that we're able to exceed our plan and revenue I -- I think we've got a pretty good handle on our operating expenses. So our goal is going to be to drive as much revenue as we can keep the belt as tight as we can and certainly burn less than we did last year.

Got it, thanks I will get back in queue.

Thank you. And I am not showing any further questions, and I would like to turn the call back over to Raj Ketkar for any closing remarks.

Charlotte, I don't have any anything to add, we appreciate everybody calling in today. And we look forward to continuing to work with you all.

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Everyone have a great day.